Physician profile
Naba Ul Saeed
NPI 1558712257
$801.87
in general payments reported to CMS, 2019-2025
12 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $167 · 2024: $521 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.18 | 2023-2025 | Rinvoq, Linzess, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.79 | 2023-2024 | Trulance, Xifaxan |
| Pentax of America, INC. | $69.01 | 2024 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Janssen Biotech, INC. | $35.49 | 2024-2025 | Tremfya, Stelara |
| Micro-Tech Endoscopy USA, INC. | $35.28 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.43 | 2023-2025 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $33.15 | 2024 | Dificid |
| Mallinckrodt Hospital Products INC. | $22.42 | 2024 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $22.21 | 2024 | Voquezna |
| Qol Medical, LLC | $21.35 | 2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $19.65 | 2025 | |
| Genzyme Corporation | $18.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naba Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.